Niagen Bioscience Inc
OCD1
Company Profile
Business description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Contact
10900 Wilshire Boulevard
Suite 600
Los AngelesCA90024
USAT: +1 310 388-6706
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
104
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.30 | 4.70 | 0.05% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,690.53 | 192.40 | 0.75% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 49,507.21 | 505.71 | 1.03% |
| NZX 50 Index | 13,333.40 | 76.63 | 0.58% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,621.40 | 0.10 | -0.00% |
| SSE Composite Index | 3,890.45 | 14.08 | 0.36% |